Journal
BMC CANCER
Volume 19, Issue -, Pages -Publisher
BMC
DOI: 10.1186/s12885-019-5921-9
Keywords
Hyperprogression; Immunotherapy; Digestive system; Tumor growth kinetics (TGK); irRECIST
Categories
Funding
- National Key Research and Development Program of China [2017YFC1308900]
- Beijing Municipal Administration of Hospitals' Youth Program [QML20171102]
- Clinical Medicine Plus X-Young Scholars Project of Peking University
Ask authors/readers for more resources
BackgroundImmune checkpoint inhibitors (ICIs) were approved to have a significant antitumor activity in various tumor types. In practice, some patients do not seem to benefit from ICIs but rather to have accelerating disease. The aim of this study was to evaluate hyperprogression in patients with malignant tumors of digestive system treated with ICIs.MethodsMedical records from consecutive patients with malignant tumors of digestive system treated with ICIs in Peking University Cancer Hospital were retrospectively collected. Tumor growth kinetics (TGK) on immunotherapy and TGK pre-immunotherapy were collected and TGK ratio (TGKR) was calculated. Hyperprogression was defined as TGKR >= 2.ResultsFrom August 2016 to May 2017, 25 evaluable patients were identified from 45 patients with malignant tumors of digestive system. Five patients were considered as having hyperprogression. Three of 5 were neuroendocrine carcinomas (NECs) and the other 2 were adenocarcinomas. Four of 5 were treated with programmed cell death ligand 1 (PD-L1) inhibitor, the other one was treated with PD-L1 inhibitor combined with cytotoxic T lymphocyte associated antigen-4 (CTLA-4) inhibitor. Pseudoprogression was observed in 2 patients.ConclusionsHyperprogression was observed in a fraction of patients with malignant tumors of digestive system treated with ICIs. Further investigation is urgently needed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available